Managing the lactating sow for optimal weaning and rebreeding performance.

Management of the lactating sow influences milk production and subsequent reproduction through changes in nutrient intake. The management goal during lactation is to maximize feed intake. Decreasing the effective environmental temperature, increasing the nutrient density of the lactation diet, maintaining fresh adequate supplies of feed and water, and preventing excess weight gain during the prior gestation period will increase nutrient intake during lactation. Effective environmental temperature of the lactating sow can be maintained in the thermoneutral zone by using drip cooling, increased ventilation rates and flooring materials with superior conductive properties. Sow parity, genetics, litter size, and disease level will also influence feed intake. Management practices must account for these factors and, thus, should be tailored to individual farm situations to ensure adequate nutrient intake and prevent aberrations in subsequent reproductive performance.     

Ultrastructure of the tubular glands in the isthmus region of the oviduct in laying and natural moulting commercial egg‐type chickens

The study investigated the ultrastructural characteristics of tubular gland and duct cells, as well as luminal gland cells in the isthmus region of the oviduct of laying and natural moulting hens. Tubular glands in laying birds were composed of type 1 and 2 cells. Based on the preponderance of each cell type, in relation to the location of a developing egg in the oviduct of the domestic fowl, these gland cells may represent different functional states of the same cell. The findings of the study on natural moulting birds suggest that autophagy is a process confined to the early stages of degeneration, while necrosis occurs in the terminal stages.     

Effects of iron injection timing on suckling and subsequent nursery and growing-finishing performance and hematological criteria

Two experiments were conducted to evaluate the effects of Fe injection timing after birth on suckling and subsequent nursery and growing-finishing pig performance. The injectable Fe source used in both experiments was GleptoForte (Ceva Animal Health, LLC., Lenexa, KS). GleptoForte contains gleptoferron which is a Fe macromolecule complex. In Exp. 1, a total of 324 newborn pigs (DNA 241 × 600, initially 1.6 ± 0.04 kg body weight [BW]) within 27 litters were used. Two days after birth, all piglets were weighed, and six barrows and six gilts per litter were allotted to 1 of 6 treatments consisting of no Fe injection or 200 mg of injectable Fe provided in a single injection on d 2, 4, 6, 8, or 10 of age. Pigs were weaned (~21 d of age) and allotted to nursery pens with all pigs in each pen having received the same Fe treatment. In Exp. 2, a total of 1,892 newborn pigs (PIC 359 × C40; initially 1.5 ± 0.02 kg BW) within 172 litters were used. One day after birth, piglets were weighed, and 11 pigs within each litter were allotted to 1 of 6 treatments consisting of no Fe injection or 200 mg of injectable Fe provided on d 1, 3, 5, or 7 of age, or 200 mg on d 1 plus 200 mg on d 12 of age. Pigs were weaned (19 d of age) and placed in a commercial wean-to-finish facility in a total of 15 pens with equal representation of treatments in each pen. In both experiments, not providing an Fe injection after birth decreased (P < 0.05) preweaning average daily gain (ADG), weaning weight, and hemoglobin and hematocrit values compared with all other treatments. In Exp. 1, increasing the age that piglets received an Fe injection until 4 or 6 d after birth provided marginal evidence for an improvement (quadratic; P = 0.070) in preweaning ADG. For the nursery period, increasing the age that piglets received an Fe injection improved (quadratic; P = 0.013) d 80 BW, but there was no evidence of a difference (P > 0.10) in d 173 BW at the end of the grow-finish period. In Exp. 2, increasing the age that piglets received a 200 mg Fe injection showed no evidence of difference (P > 0.10) for subsequent nursery and growing-finishing ADG. In both experiments, hemoglobin and hematocrit values were decreased (linear; P < 0.05) at weaning with increasing age when pigs received an Fe injection. These experiments suggest that providing a 200 mg Fe injection within 7 d after farrowing is sufficient for optimizing preweaning and subsequent growth performance.     

Effects of feeding schedule on body condition, aggressiveness, and reproductive failure in group-housed sows

A total of 208 sows and 288 gilts (PIC line C29) were used to determine the influence of feeding frequency (2 vs. 6 times/d, floor fed) on performance and welfare measurements on a commercial sow farm. Treatments consisted of feeding similar amounts of feed to each sow (2.5 kg) or gilt (2.05 kg) over 2 (0700 and 1530) or 6 times daily (0700, 0730, 0800, 1530, 1600, and 1630). There were 8 sows or 12 gilts in each pen. Gilts and sows were moved to pens 1 to 4 d after breeding. In sows, there were no differences (P > 0.10) in ADG, backfat change, or variation in BW. There was a trend (P < 0.08) for sows fed twice daily to farrow more total pigs born, but number born alive or other reproductive performance traits were not different (P > 0.10) among treatments. Sows fed 6 times per day had increased vocalization during the morning (P < 0.07) and afternoon (P < 0.01) feeding periods compared with sows fed twice daily. Sows fed twice daily had more skin (P < 0.01) and vulva (P < 0.04) lesions as well as a small increase in feet and leg (P < 0.01) and hoof (P < 0.02) problems. In this commercial facility, the standard management protocol required moving gilts to a different gestation facility on d 42. On d 42, two pens of gilts with similar breeding dates and treatment were combined and moved to another facility with larger pens until farrowing. Gilts fed 6 times daily had a tendency for greater ADG (P < 0.07) from d 0 to 42 and a tendency for greater (P < 0.09) backfat on d 42. After movement to the larger groups from d 42 to farrowing, ADG was similar (P > 0.10) for gilts fed 2 or 6 times daily. Gilts fed twice daily had lower BW variation at d 42 (P < 0.04) and tended to at farrowing (P < 0.10). In gilts, there were no differences (P > 0.10) for reproductive performance, skin and vulva lesions, and feet and leg scores. In conclusion, there were few growth, farrowing, or aggression differences among gilts fed 2 or 6 times daily. This suggests that either feeding method is suitable for group-housed gilts. Among sows, feeding frequency resulted in few growth or farrowing performance differences. Feeding 6 times daily resulted in a small but significant reduction in skin and vulva lesions and structural problem scores while increasing vocalization. Increasing the feeding frequency from 2 to 6 times daily does not appear to have a negative or positive impact on performance or welfare of group-housed gilts and sows.     

Carvedilol in dogs with dilated cardiomyopathy

BACKGROUND: Dilated cardiomyopathy (DCM) is characterized by reduced systolic function, heightened sympathetic tone, and high morbidity and mortality. Little is known regarding the safety and efficacy of beta-blocker treatment in dogs with DCM. HYPOTHESIS: Carvedilol improves echocardiographic and neurohormonal variables in dogs with DCM over a 4-month treatment period. METHODS: Prospective, placebo-controlled, double-blinded randomized study. Dogs with DCM underwent echocardiography, ECG, thoracic radiographs, and neurohormonal profiling, followed by titration onto carvedilol (0.3 mg/kg q12h) or placebo over a 4-week period and subsequently received 3 months of therapy. Primary study endpoints included left ventricular volume and function. RESULTS: Sixteen dogs received carvedilol and 7 received placebo. At study end, 13 carvedilol dogs and 5 placebo dogs were alive. There was no difference in the mean percentage change in left ventricular volume at end-diastole (LVVd), left ventricular end-systolic volume (LVVs), and ejection fraction (EF) between treatment groups, suggesting that both groups experienced similar amounts of disease progression. Carvedilol treatment did not result in significant changes in neurohormonal activation, radiographic heart size, heart rate, or owner perceived quality-of-life. Baseline B-type natriuretic peptide (BNP) predicted dogs in the carvedilol-treated group that maintained or improved their EF over the study duration. CONCLUSIONS AND CLINICAL IMPORTANCE: Carvedilol administration did not improve echocardiographic or neurohormonal indicators of heart function. The lack of effect may be related to severity of disease, carvedilol dose, or brevity of follow-up time. Statistical power of the present study was adversely affected by a high fatality rate in study dogs and small sample size.